Evidence map›Paper›PMID 25830316›Full record

ArticlePloS one2015

HCV genotyping from NGS short reads and its application in genotype detection from HCV mixed infected plasma.

Ping Qiu, Richard Stevens, Bo Wei, Fred Lahser, Anita Y M Howe, Joel A Klappenbach, Matthew J Marton

Abstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ping QiuMolecular Biomarker and Diagnostics, Merck Research Laboratories, Rahway, New Jersey, United States of America.
Richard StevensTarget & Pathway Biology, Merck Research Laboratories, Boston, Massachusetts, United States of America.
Bo WeiMolecular Biomarker and Diagnostics, Merck Research Laboratories, Rahway, New Jersey, United States of America.
Fred LahserInfectious Diseases and Clinical Virology, Merck Research Laboratories, Kenilworth, New Jersey, United States of America.
Anita Y M HoweInfectious Diseases and Clinical Virology, Merck Research Laboratories, Kenilworth, New Jersey, United States of America.
Joel A KlappenbachTarget & Pathway Biology, Merck Research Laboratories, Boston, Massachusetts, United States of America.
Matthew J MartonMolecular Biomarker and Diagnostics, Merck Research Laboratories, Rahway, New Jersey, United States of America.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Genotyping of hepatitis C virus (HCV) plays an important role in the treatment of HCV. As new genotype-specific treatment options become available, it has become increasingly important to have accurate HCV genotype and subtype information to ensure that the most appropriate treatment regimen is selected. Most current genotyping methods are unable to detect mixed genotypes from two or more HCV infections. Next generation sequencing (NGS) allows for rapid and low cost mass sequencing of viral genomes and provides an opportunity to probe the viral population from a single host. In this paper, the possibility of using short NGS reads for direct HCV genotyping without genome assembly was evaluated. We surveyed the publicly-available genetic content of three HCV drug target regions (NS3, NS5A, NS5B) in terms of whether these genes contained genotype-specific regions that could predict genotype. Six genotypes and 38 subtypes were included in this study. An automated phylogenetic analysis based HCV genotyping method was implemented and used to assess different HCV target gene regions. Candidate regions of 250-bp each were found for all three genes that have enough genetic information to predict HCV genotypes/subtypes. Validation using public datasets shows 100% genotyping accuracy. To test whether these 250-bp regions were sufficient to identify mixed genotypes, we developed a random primer-based method to sequence HCV plasma samples containing mixtures of two HCV genotypes in different ratios. We were able to determine the genotypes without ambiguity and to quantify the ratio of the abundances of the mixed genotypes in the samples. These data provide a proof-of-concept that this random primed, NGS-based short-read genotyping approach does not need prior information about the viral population and is capable of detecting mixed viral infection.

Indexed as

Genes, ViralGenotypeHepacivirusHepatitis CHigh-Throughput Nucleotide SequencingHumansMolecular Diagnostic TechniquesMolecular TypingPhylogenySequence Analysis, DNA

Identifiers

PMID25830316
PMCPMC4382110

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.